Dennis Matheis Purchases 245,000 Shares of Lucid Diagnostics (NASDAQ:LUCD) Stock

Lucid Diagnostics Inc. (NASDAQ:LUCD) Director Dennis Matheis purchased 245,000 shares of Lucid Diagnostics stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $1.00 per share, for a total transaction of $245,000.00. Following the transaction, the director directly owned 1,033,443 shares of the company’s stock, valued at $1,033,443. The trade was a 31.07% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Lucid Diagnostics Stock Performance

Shares of LUCD opened at $1.07 on Friday. The company’s fifty day moving average is $1.16 and its 200 day moving average is $1.18. Lucid Diagnostics Inc. has a fifty-two week low of $0.90 and a fifty-two week high of $1.70. The stock has a market capitalization of $217.28 million, a PE ratio of -2.28 and a beta of 1.10.

Lucid Diagnostics (NASDAQ:LUCD) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.38 million. As a group, research analysts forecast that Lucid Diagnostics Inc. will post -0.22 earnings per share for the current year.

Wall Street Analyst Weigh In

LUCD has been the topic of several research reports. BTIG Research restated a “buy” rating and issued a $2.50 price target on shares of Lucid Diagnostics in a research report on Friday, May 15th. Needham & Company LLC restated a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a research report on Thursday, March 26th. Ascendiant Capital Markets boosted their price target on shares of Lucid Diagnostics from $8.25 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Wall Street Zen cut shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Maxim Group cut their price objective on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $4.13.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Lucid Diagnostics by 9.6% in the third quarter. Vanguard Group Inc. now owns 4,523,997 shares of the company’s stock worth $4,569,000 after purchasing an additional 396,719 shares during the last quarter. Masters Capital Management LLC grew its holdings in shares of Lucid Diagnostics by 46.6% in the third quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock worth $4,039,000 after purchasing an additional 1,272,000 shares during the last quarter. Aberdeen Group plc grew its holdings in shares of Lucid Diagnostics by 38.3% in the fourth quarter. Aberdeen Group plc now owns 3,457,894 shares of the company’s stock worth $3,769,000 after purchasing an additional 957,894 shares during the last quarter. Two Seas Capital LP bought a new position in shares of Lucid Diagnostics in the third quarter worth about $3,030,000. Finally, Ghisallo Capital Management LLC bought a new position in shares of Lucid Diagnostics in the third quarter worth about $2,990,000. 74.01% of the stock is currently owned by institutional investors.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.